Intensive combination chemotherapy in treatment of CML

Bone Marrow Transplantation

Volumn 17, Issue SUPPL. 3, 1996, Pages

  Lengfelder, E ^a   Hehlmann, R ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CML; Intensive combination chemotherapy; Interferon

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; ASPARAGINASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HYDROXYUREA; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG TOXICITY; HUMAN; LEUKOCYTE COUNT; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; GERMANY; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC-PHASE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LEUKOCYTE COUNT; SURVIVAL RATE;

EID: 0029942281     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330: 827-838.
2. Hehlmann R, Heimpel H, Hasford J et al. and the German CML Study Group. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia (CML). Blood 1994; 84: 4064-4077.
3. Hehlmann R. Cytostatic therapy in chronic myelogenous leukemia: review and perspectives. In: Huhn D, Hellriegel KP, Niederle N (eds.). Chronic Myelocytic Leukemia and Interferon. Berlin: Springer, 1988; 102-112.
4. Minot GR, Buckman TE, Isaacs R. Chronic myelogenous leukemia. Age, incidence, duration and benefit derived from treatment. J Am Med Assoc 1924; 82: 1489-1494.
5. Medical Research Council's Working Party for Therapeutic Trials in Leukemia. Chronic granulocytic leukemia. Comparison of radiotherapy and busulfan therapy. Br Med J 1968; 1: 201-208.
6. Hehlmann R, Heimpel H, Hasford J et al. and the German CML Study Group. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia (CML). Prolongation of survival by hydroxyurea. Blood 1993; 82: 398-407.
7. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-825.
8. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M and the Leukemia Service: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med 1995; 112: 254-261.
9. McGlave PB, De Fabritiis P, Deisseroth A et al. Autologous transplants for chronic myelogenous leukemia. Results from eight transplant groups. Lancet 1994; 343: 1486-1488.
10. Brodsky I, Fuscaldo KE, Kahn SB, Conroy JF: Myeloproliferative disorders. II. CML. Clonal evolution and its role in management. Leuk Res 1979; 3: 379-393.
11. 1 + chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Blood 1979; 53: 375-395.
12. Sharp JC, Joyner MV, Wayne AW et al. Karyotypic conversion in Ph-1-positive chronic myeloid leukemia with combination chemotherapy. Lancet 1979; 1: 1370-1372.
13. 1 + chronic myelogenous leukemia and effects of intensive treatment. Blood 1982; 59: 793-808.
14. Kantarjian HM, Vellekoop L, McCredie KB et al. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 1985; 3: 192-200.
15. Kantarjian HM, Talpaz M, Kurzrock R et al. Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. Acta Haematol 1987; 78 (Suppl. 1): 70-74.
16. Kantarjian HM, Talpaz M, Keating MJ et al. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosomepositive chronic myelogenous leukemia. Cancer 1991; 68: 1201-1207.
17. Simonsson B, Öberg G, Killander A et al. Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia. Stem Cells 1993; 11 (Suppl. 3): 73-76.
18. Carella AM, Podesta M, Frassoni F et al. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 1993; 12: 267-271.
19. Gale RP, Baccarani M, Horowitz MM, Zhang MJ. Is the course of chronic myelogenous leukemia affected by bone marrow transplantation? An analysis in patients relapsing after bone marrow transplants. Blood 1993; 92 (Suppl. 1): 167 (Abstract).